247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study

MLA

Andreas Schneeweiss, et al. “247P Efficacy and Safety of Ribociclib (RIB) in Combination with Letrozole (LET) in Patients with Estrogen Receptor–positive Advanced Breast Cancer (ABC): Secondary and Exploratory Results of Phase 3b RIBECCA Study.” Annals of Oncology, vol. 32, Sept. 2021, pp. S467–68. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.08.530.

APA

Andreas Schneeweiss, Wolfgang Janni, Tanja Fehm, Claudia Quiering, J Kreuzeder, Hans Tesch, Sara Y. Brucker, Mattea Reinisch, S Kümmel, Christian M. Kurbacher, Andreas D. Hartkopf, Thomas Decker, Arnd Nusch, Bernhard Heinrich, Diana Lüftner, Petra Krabisch, R. Fuchs, J Huober, Martin Schuler, & Peter A. Fasching. (2021). 247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study. Annals of Oncology, 32, S467–S468. https://doi.org/10.1016/j.annonc.2021.08.530

Chicago

Andreas Schneeweiss, Wolfgang Janni, Tanja Fehm, Claudia Quiering, J Kreuzeder, Hans Tesch, Sara Y. Brucker, et al. 2021. “247P Efficacy and Safety of Ribociclib (RIB) in Combination with Letrozole (LET) in Patients with Estrogen Receptor–positive Advanced Breast Cancer (ABC): Secondary and Exploratory Results of Phase 3b RIBECCA Study.” Annals of Oncology 32 (September): S467–68. doi:10.1016/j.annonc.2021.08.530.